Memory Pharmaceuticals Announces Results For Phase 2a Trial Of MEM 1003 In Alzheimer's Disease

Memory
Pharmaceuticals Corp. (Nasdaq: MEMY) announced top-line data from the
multi-center, randomized, double-blind, placebo-controlled Phase 2a study
of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's
disease. The trial enrolled 183 subjects with mild to moderate Alzheimer's
disease at over 40 centers in the United States and included monotherapy
subjects and subjects on stable doses of cholinesterase inhibitors. The
trial failed to meet its primary endpoint, which was a twelve-week mean
change in the Alzheimer's disease Assessment Scale -- Cognitive subscale
(ADAS-cog) score in the overall population.



The negative results were largely driven by an unusually large placebo
response in the subgroup of monotherapy subjects. In the subgroup of
subjects receiving cholinesterase inhibitors, the change in ADAS-cog
favored treatment over placebo, although this difference was not
statistically significant. Similarly, in this subgroup, numeric
improvements were seen in all of the four secondary endpoints, which
included the Mini-Mental State Exam, the Alzheimer's Disease Cooperative
Study -- Activities of Daily Living, the Clinician Interview-Based
Impression of Change with Caregiver Input and the Neuropsychiatric
Inventory.



"Based on this information, I believe that further development of this
compound merits consideration," said Pierre N. Tariot, M.D., Professor of
Research Psychiatry, Director of the Memory Disorders Center of the Banner
Alzheimer's Institute in Phoenix, and chairman of the study's data and
safety monitoring board.



"While we are disappointed that the trial did not meet the primary
endpoint, we are encouraged by the favorable trend seen in the subgroup of
subjects receiving cholinesterase inhibitors," said Stephen R. Murray,
M.D., Ph.D., Chief Medical Officer. "Clearly there is a significant need
for new options for the treatment of Alzheimer's disease, and we believe
that the effects of MEM 1003 seen in this study warrant further
investigation."



Subjects participating in the study were randomized at enrollment into
one of three treatment groups -- 30 mg of MEM 1003 twice a day, 90 mg of
MEM 1003 twice a day or placebo twice a day. During the double-blind
treatment segment of the study, subjects received MEM 1003 or placebo for a
period of 12 weeks, which was followed by a four-week single-blind placebo
treatment. Secondary measures assessed changes in activities of daily
living, behavior and global function.



MEM 1003 was generally well-tolerated in the trial. The rates of
treatment-emergent adverse events were similar in all arms of the trial.
There were seven treatment-emergent serious adverse events (SAEs) in five
subjects, including two deaths. Four of the subjects were in the 30 mg dose
group and the fifth subject was in the 90 mg dose group. None of the SAEs
were deemed to be treatment-related by the investigators.
















The Company expects to report top-line results from its Phase 2a
clinical trial of MEM 3454, its lead nicotinic alpha-7 agonist, in
Alzheimer's disease by the middle of the fourth quarter.



About MEM 1003



MEM 1003 is a neuronal L-type calcium channel modulator that Memory
Pharmaceuticals is developing for the treatment of Alzheimer's disease. By
blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium
and reestablish normal levels of calcium, which may help treat and prevent
the onset of Alzheimer's disease.



About the Company



Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused
on developing innovative drugs for the treatment of debilitating CNS
disorders such as Alzheimer's disease, schizophrenia, depression and
bipolar disorder. For additional information, please visit our website at
memorypharma.



Safe Harbor Statement



This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks and uncertainties. All statements, other than statements
of historical facts, regarding management's expectations, beliefs, goals,
plans or Memory Pharmaceuticals' prospects, future financial position,
future revenues and projected costs should be considered forward-looking.
Readers are cautioned that actual results may differ materially from
projections or estimates due to a variety of important factors, including
the outcome of clinical trials of Memory Pharmaceuticals' drug candidates
and whether they demonstrate these candidates' safety and effectiveness;
the risks and uncertainties associated with: obtaining additional financing
to support Memory Pharmaceuticals' R&D and clinical activities and
operations; obtaining regulatory approvals to conduct clinical trials and
to commercialize Memory Pharmaceuticals' drug candidates; Memory
Pharmaceuticals' ability to enter into and maintain collaborations with
third parties for its drug development programs; Memory Pharmaceuticals'
dependence on its collaborations and its license relationships; achieving
milestones under Memory Pharmaceuticals' collaborations; Memory
Pharmaceuticals' dependence on preclinical and clinical investigator s,
preclinical and clinical research organizations, manufacturers and
consultants; and protecting the intellectual property developed by or
licensed to Memory Pharmaceuticals. These and other risks are described in
greater detail in Memory Pharmaceuticals' filings with the Securities and
Exchange Commission. Memory Pharmaceuticals may not actually achieve the
goals or plans described in its forward-looking statements, and investors
should not place undue reliance on these statements. Memory Pharmaceuticals
disclaims any intent or obligation to update any forward-looking statements
as a result of developments occurring after the date of this press release.


Memory Pharmaceuticals Corp.

memorypharma